

ADMEDUS Ltd ABN 35 088 221 078

REGISTERED OFFICE:

Level 1, 197 Adelaide Terrace Perth Western Australia 6000

> PO Box 6879 East Perth Western Australia 6892

T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

7 October 2014

Centralised Company Announcements Platform Australian Stock Exchange 10th floor, 20 Bond Street Sydney NSW 2000

Dear Sir / Madam,

#### Appendix 3B - Exercise of Options & Issue of Shares

The Board of Directors of Admedus Ltd (ASX: AHZ) hereby announces that 83,333 ordinary shares have been allotted upon the clearing of receipts totalling \$7,916.64 on exercise of 83,333 options exercisable at \$0.095.

The Company has also allotted 200,937 shares each at a deemed issue price of \$0.1493 (based on a 10 day VWAP at 3 October 2014) to contractor of the Company for services provided.

Refer to the attached Appendix 3B and section 708A(5)(e) of the Corporations Act notice.

Yours sincerely

For and on behalf of Admedus Limited

Stephen Mann Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

documents given to ASX become ASX's property and may be made public.		
$Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12$		
	of entity	
ADMI	EDUS LIMITED	
ABN		
35 088	3 221 078	
We (th	ne entity) give ASX the following infor	rmation.
Par	t 1 - All issues	
You mi	ust complete the relevant sections (attach sh	heets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to	Ordinary shares fully paid
1	be issued	Ordinary shares runy paid
2	X 1 61 11 11 1	a) 83,333
2	Number of +securities issued or to be issued (if known) or maximum	a) 83,333 b) 200,937
	number which may be issued	.,,
3	Principal terms of the +securities	Ordinary shares fully paid ranking equally with
3	(eg, if options, exercise price and	existing ordinary shares fully paid.
	expiry date; if partly paid	
	+securities, the amount outstanding	
	and due dates for payment; if +convertible securities, the	
	conversion price and dates for	
	conversion)	

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	<ul> <li>a) \$0.095 per option exercised (Total \$7,916.64)</li> <li>b) \$0.1493 based on a 10 day VWAP at 3 October 2014 (Total \$30,000)</li> </ul>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>a) Exercise of listed \$0.09 options exp 18/06/2018</li> <li>b) Payment for contractor services</li> </ul>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	20 November 2013
6с	Number of *securities issued without security holder approval under rule 7.1	200,937
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under	92 222 (Evention 4)	
01	an exception in rule 7.2	83,333 (Exception 4)	
бg	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1	Listing Rule 7.1 capacity:	120,682,251
	and release to ASX Market Announcements	Listing Rule 7.1A capacity	v: 135,922,125
7		60 + 1 2014	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	6 October 2014	
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	1,442,422,191	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
15,000,000	21/05/19
	\$0.17 options
2 000 000	1/2/10
2,000,000	1/2/19
	\$0.245 options
3,000,000	01/07/18
2,000,000	\$0.17 options
	+ + + + + + + + + + + + + + + + + + +
9,000,000	16/12/18
	\$0.27 options
15,216,667	18/06/18
	\$0.095 options
2,000,000	01/03/18
2,000,000	\$0.06 options
	φο.σσ σρασίιs
2,466,667	18/05/17
	\$0.06 options
3,666,667	10/7/16
	\$0.06 options
51 400 000	10/7/16
51,400,000	\$0.06 options
	φυ.σο options
5,000,000	22/10/14
-,,	\$0.10 options
	•

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of	N/A

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do *security holders dispose ir entitlements (except by sale th a broker)?	N/A	
33	<sup>+</sup> Desp	atch date	N/A	
	_	Quotation of securit		
You nee	ed only c	omplete this section if you are appl	ying for quotation of securities	
34	Type (tick o	of securities <i>me</i> )		
(a)		Securities described in Part 1		
(b)			of the escrowed period, partly paid securities that become fully paid, employee nds, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a)				
Addi	itiona	l securities forming a	new class of securities	
Tick to docume		e you are providing the informat	ion or	
35		additional *securities, and the those holders	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by	
36		+securities setting out the num 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	y securities, a distribution schedule of the additional ber of holders in the categories	
37		N/A A copy of any trust deed for th N/A	ne additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	N/A	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the <sup>+</sup>securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Mann	Date: 7 October 2014
	Company secretary	
Print name:	Stephen Mann	

16.10

Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,043,521,681	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	102,683,333	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	213,016,240	
Number of partly paid ordinary securities that became fully paid in that 12 month period	0	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	1,359,221,254	

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	203,883,188	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	83,200,937	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	83,200,937	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	203,883,188	
Note: number must be same as shown in Step 2		
Subtract "C"	83,200,937	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	120,682,251	
	[Note: this is the remaining placement capacity under rule 7.1]	

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	1,359,221,254	
Step 2: Calculate 10% of "A"  "D"	0.10 Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	135,922,125	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul> </li> </ul>	Nil	
line items "E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10  Note: number must be same as shown in Step 2	135,922,125
Subtract "E"  Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" x 0.10] – "E"	135,922,125 Note: this is the remaining placement capacity under rule 7.1A



#### **ASX ANNOUNCEMENT**

#### Notice under Section 708A(5)(e) of the Corporations Act

7 October 2014

On 6 October 2014, Admedus Limited (**Company**) issued 83,333 shares pursuant to Section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Act**). The Company advises that the Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under the section 708 or 708A. By the Company giving this notice, a sale of the Securities noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- 1. the Company issued the securities without disclosure to investors under Part 6D.2 of the Act;
- 2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- 3. as at the date of this notice, there is no information:
  - (a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - (i) the assets and liabilities, financial position and performance, profits and losses and prospect and prospects of the Company; or
    - (ii) the rights and liabilities attaching to the securities.

Yours faithfully

Stephen Mann Company Secretary

**Admedus Limited**